Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
C-Rad AB Class B ( ($SE:CRAD.B) ) has provided an announcement.
C-RAD showcased its latest developments at ASTRO 2025, emphasizing tools that enhance cancer care by improving user experience and workflow efficiency. The introduction of Catalyst+ LITE offers clinics a scalable entry into Surface Guided Radiation Therapy, with features like high-precision motion management and tattoo-less patient setup. These innovations, including a new ergonomic workflow and six degrees of freedom patient alignment, aim to streamline clinical operations and reinforce C-RAD’s commitment to patient-centric care.
The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.
More about C-Rad AB Class B
C-RAD develops surface-guided imaging solutions for radiation therapy, focusing on accurate dose delivery to tumors while protecting healthy tissue. Utilizing high-speed 3D cameras and augmented reality, C-RAD enhances patient setup and motion monitoring during treatment, ensuring safety and comfort without additional imaging doses. The company is listed on NASDAQ Stockholm.
Average Trading Volume: 41,078
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.03B
See more insights into CRAD.B stock on TipRanks’ Stock Analysis page.